{"id":"erypo-janssen-cilag","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Thrombotic events (venous thromboembolism, stroke)"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"5-10","effect":"Flu-like symptoms"},{"rate":"<1","effect":"Pure red cell aplasia (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This mechanism is used to treat anemia by increasing hemoglobin and hematocrit levels.","oneSentence":"ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:25.116Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing elective surgery"}]},"trialDetails":[{"nctId":"NCT00666835","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-04","conditions":"Anemia","enrollment":478},{"nctId":"NCT00711958","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-11","conditions":"Anemia","enrollment":114},{"nctId":"NCT01392612","phase":"PHASE4","title":"Erythropoietin and Platelet Activation Markers","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-11","conditions":"Thrombosis, Hypertension","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EPREX®","Solution for i.v. injection"],"phase":"phase_3","status":"active","brandName":"ERYPO®, Janssen-Cilag","genericName":"ERYPO®, Janssen-Cilag","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ERYPO® (epoetin alfa) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing elective surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}